KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.

Kevin M Alexander, Margot K Davis, Olakunle Akinboboye, John Berk, Kunal Bhatt, Francesco Cappelli, Sarah A M Cuddy, Marianna Fontana, Pablo Garcia-Pavia, Julian D Gillmore, Jan M Griffin, Justin L Grodin, Daniel P Judge, Michel G Khouri, Kaitlyn Lam, Ahmad Masri, Mathew S Maurer, Laura Obici, Frederick L Ruberg, Nitasha Sarswat, Keyur Shah, Prem Soman, Lily Stern, Richard Wright, Kuangnan Xiong, Xiaofan Cao, Ted Lystig, Jean-François Tamby, Adam Castaño, Leonid Katz, Uma Sinha, Jonathan C Fox, Scott D Solomon, Martha Grogan

JAMA Cardiol 11(1) 57-67

PMID41205147
PMCIDPMC12596743
DOI10.1001/jamacardio.2025.4477
发表日期2025-11-08
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图;Figure 2.:森林图/亚组分析图;Figure 3.:生活质量量表图;Figure 4.:非 KM 图。
摘要

摘要

IMPORTANCE: Transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive disease caused by misfolded transthyretin (TTR), occurs as wild-type (ATTRwt-CM) or variant (ATTRv-CM) forms. p.Val142Ile is the most common variant in the US, linked to rapid progression and increased mortality. Acoramidis achieves near-complete (≥90%) TTR stabilization and showed clinical benefit in the 30-month ATTRibute-CM trial and through month 42 in the ongoing open-label extension (OLE). OBJECTIVE: To evaluate the efficacy of acoramidis in ATTRwt-CM, ATTRv-CM, and variant subgroups (p.Val142Ile and non-p.Val142Ile). DESIGN, SETTING, AND PARTICIPANTS: This international, multicenter, phase 3, randomized placebo-controlled study took place from April 2019 to May 2023 with ongoing OLE (month 42). ATTRibute-CM enrolled 632 participants with ATTR-CM; 611 of 632 were included in the modified intention-to-treat (mITT) population. There were 380 participants who continued into the OLE. These data were analyzed from January 2025 to July 2025. INTERVENTIONS: Oral acoramidis, 712 mg, or placebo twice daily for 30 months, followed by 12 months of open-label treatment. MAIN OUTCOMES AND MEASURES: All-cause mortality (ACM), cardiovascular-related hospitalizations (CVH), serum TTR, 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire Overall Summary score, and N-terminal pro B-type natriuretic peptide in participants with ATTRwt-CM and ATTRv-CM. Post-hoc analyses were conducted in variant subgroups, including p.Val142Ile. RESULTS: Overall, 552 participants with wild-type ATTR-CM (mean [SD] age, 78 [6.3] years; 92.0% male and 8.0% female) and 59 participants with variant ATTR-CM (mean [SD] age, 73 [7.7] years; 77.3% male and 22.7% female) were randomized (mITT population), including 35 with p.Val142Ile. Consistent efficacy was observed in wild-type and variant subgroups for ACM/CVH through month 30 and ACM through month 42. At month 30, acoramidis reduced the risk of ACM/first CVH vs placebo by 31% in ATTRwt-CM (hazard ratio [HR], 0.69; 95% CI, 0.52-0.90; P = .007) and by 59% in ATTRv-CM (HR, 0.41; 95% CI, 0.21-0.81; P = .01). ACM was reduced through month 42 with HRs of 0.70 (95% CI, 0.50-0.98; P = .04) and 0.41 (95% CI, 0.19-0.93; P = .03) in the ATTRwt-CM and ATTRv-CM groups, respectively. Consistent treatment benefit was observed in participants with ATTRwt-CM and ATTRv-CM for secondary end points. Within variant subgroups (p.Val142Ile vs non-p.Val142Ile), consistent treatment benefits were observed for ACM/CVH through month 30 and ACM through month 42. CONCLUSIONS AND RELEVANCE: The beneficial effect of acoramidis was observed consistently in ATTRwt-CM and ATTRv-CM groups. These hypothesis-generating results indicate that further studies are warranted to better characterize the therapeutic benefit of acoramidis in variant subgroups. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT03860935; NCT04988386.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Forest Plots for Efficacy Outcomes by Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Genotype Forest plots of the modified intention-to-treat population by ATTR-CM genotype for the primary 4-component hierarchical end point at month 30 (A), time to all-cause mortality (ACM) or first cardiovascular hospitalization (CVH) from baseline through month 30 (B), frequency of CVH from baseline through month 30 (C), and time to ACM from baseline through month 42 (D). ACM included 1 participant with wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) in the placebo arm who received an implanted cardiac mechanical assist device and 1 participant with variant transthyretin amyloid cardiomyopathy (ATTRv-CM) in the placebo arm who received a heart transplant. F-S indicates Finkelstein and Schoenfeld. a P value from testing the interaction of subgroup × treatment and other P values are for testing the treatment difference at a given value of subgroup variable.
非 KM Figure
Figure 2.Kaplan-Meier Curves for Time to All-Cause Mortality (ACM) or First Cardiovascular Hospitalization (CVH) in the Wild-Type Transthyretin Amyloid Cardiomyopathy (ATTRwt-CM) and Variant Transthyretin Amyloid Cardiomyopathy (ATTRv-CM) Subgroups Kaplan-Meier curves of the modified intention-to-treat population for time to ACM or first CVH from baseline through month 30 in the ATTRwt-CM subgroup (A) and the ATTRv-CM subgroup (B), and time to ACM from baseline through month 42 in the ATTRwt-CM subgroup (C) and the ATTRv-CM subgroup (D).
非 KM Figure
Figure 3.Change From Baseline to Month 30 in Biomarkers, Functional Assessments, and Quality of Life in Modified Intention-to-Treat Population Mean serum transthyretin (TTR) levels change from baseline to month 30 (A) in geometric mean fold change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) (from mixed model for repeated measures) (B), 6-minute walk distance (6MWD) (C), and Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score in the wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) and variant transthyretin amyloid cardiomyopathy (ATTRv-CM) subgroups (D). Observed values are displayed. Among the 7 participants with ATTRv-CM who received placebo and completed the month 30 visit, 2 received concomitant tafamidis treatment after month 12. In the 5 participants who received placebo without concomitant tafamidis and who completed the month 30 visit, mean (SD) serum TTR was 18.4 (3.32) mg/dL at baseline and 19.0 (4.20) mg/dL at month 30. LS indicates least squares.
非 KM Figure
Figure 4.Kaplan-Meier Curves of Modified Intention-to-Treat Population for Time to All-Cause Mortality (ACM) or First Cardiovascular Hospitalization (CVH) in Participants With p.Val142Ile Variant Transthyretin Amyloid Cardiomyopathy (ATTRv-CM) Kaplan-Meier curves for time to ACM or first CVH from baseline through month 30 (A) and time to ACM from baseline through month 42 in participants with p.Val142Ile ATTRv-CM (B).
非 KM Figure